CN1472313A - Antibody against AIDS virus O and its production cell series and use - Google Patents
Antibody against AIDS virus O and its production cell series and use Download PDFInfo
- Publication number
- CN1472313A CN1472313A CNA021253714A CN02125371A CN1472313A CN 1472313 A CN1472313 A CN 1472313A CN A021253714 A CNA021253714 A CN A021253714A CN 02125371 A CN02125371 A CN 02125371A CN 1472313 A CN1472313 A CN 1472313A
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- hiv
- virus
- antibody
- epi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title claims description 18
- 238000004519 manufacturing process Methods 0.000 title description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract description 18
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 10
- 241000700605 Viruses Species 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000003053 immunization Effects 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000002649 immunization Methods 0.000 claims description 2
- 208000030507 AIDS Diseases 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 abstract description 4
- 125000000539 amino acid group Chemical group 0.000 description 10
- 230000003472 neutralizing effect Effects 0.000 description 8
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000004927 fusion Effects 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
- 229940124321 AIDS medicine Drugs 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Abstract
An antibody of the HIV-1 O-type strain, its productive cell line and its application are disclosed. Said monoclonal antibody can specifically bind with HIV-1 O-type strain, and has the specificity to epitope DE, especially to epitope ELDEWA. A mouse hybridoma cell line able to secrete said monoclonal antibody is also disclosed. Said antibody can be used to discriminate and diagnose HIV-1 O strain and to prepare the medicines for treating AIDS.
Description
Technical field
The present invention relates to antibody and the production clone and the application of AIDS virus O.
Background technology
Acquired immune deficiency syndrome (AIDS) claims acquired immune deficiency syndrome (AIDS) again, is a kind of immunological disease that is caused by human immunodeficiency virus I type (HIV-1), does not still have the active drug of thoroughly curing at present, does not also have vaccine to prevent.The high variability of immunodeficiency virus is the difficult problem in HIV vaccine and the medicinal design always.
Recently external anti-AIDS drug clinical study result proves, in passive immunotherapy, be used in combination neutralizing antibody (comprising the monoclonal antibody 2F5 of ELDKWA epitope specificity) at the several specific neutralizing epitopes on the HIV-1 membranin gp160 (precursor protein of membranin gp120 and transmembrane protein gp41), the mucous membrane that can suppress HIV-1 virus infects and mother-to-baby transmission, and can remove HIV-1 virus (Nature Medicine 1999,5:204 in the blood; Nature Medicine 2000,6:200; Nature Medicine 1999,5:211); The epitope specificity monoclonal antibody of main neutralizing epitope ELDKWA on human immunodeficiency virus (HIV-1) the transmembrane protein gp41 can the multiple HIV-1 virus strain of vitro inhibition target cell infection (J.Virology 1993,67:6642; AIDS Res.Human Retroviruses 1994,10:1651; AIDS 1996,10:587).Studies have shown that HIV-1 can escape the neutralizing effect (Immunity 10,431-438,1999) of neutralizing antibody by the restricted variation of neutralizing epitope.ELDKWA is the important HIV-1 neutralizing epitope of generally acknowledging, the conservative property of this epi-position is very strong, but in some restricted variation in D or K site, can make virus escape the neutralizing effect of monoclonal antibody.
Summary of the invention
The present inventor has found the immunology epi-position that of AIDS virus O is new after deliberation, and this epi-position comprises that the nitrogen end is aspartic acid, and one of carbon tip is two adjacent amino acid residues of L-glutamic acid.Link to each other with these two amino-acid residues, usually the terminal amino-acid residue that connects of nitrogen is a leucine, the amino-acid residue that one of carbon tip connects is a tryptophane, at this moment the amino acid residue sequence of this immunology epi-position is LDEW, on the basis of this sequence, usually the amino-acid residue of nitrogen end connection is a L-glutamic acid, and the amino-acid residue that carbon teminal connects is a L-Ala, and at this moment the amino acid residue sequence of this immunology epi-position is ELDEWA.
The contriver finds by the retrieval to HIV database (http://hiv-web.lanl.gov), the transmembrane protein gp41 of all HIV-1 virus O type strains all has ELDEWA epi-position (as shown in table 1), and other HIV-1 virus subtype does not have this epi-position, confirm that further ELDEWA is the peculiar epi-position of HIV-1 virus O type strain, can be used for the target site that the strain of HIV-1 virus O type is differentiated and diagnosed, also can be used as the target site of medicine.
The strain of table 1:HIV-1 virus O type has distinctive ELDEWA epi-position
| Accession number | Sequence | The sequence number of amino-acid residue | |
| ????1 | ????AF009033 | ????LELDEWAS | ?668-675 |
| ????2 | ????AF407418 | ????LELDEWAS | ?675-682 |
| ????3 | ????AJ302646 | ????LELDEWAS | ?680-687 |
| ????4 | ????AJ302647 | ????LELDEWAS | ?669-676 |
| ????5 | ????L20571 | ????LELDEWAS | ?674-681 |
| ????6 | ????L20587 | ????LELDEWAS | ?660-667 |
| ????7 | ????NC_002787 | ????LELDEWAS | ?680-687 |
| ????8 | ????U82990 | ????LELDEWAS | ?658-665 |
| ????9 | ????U82991 | ????LELDEWAS | ?670-677 |
| ????10 | ????U82992 | ????LELDEWAS | ?668-675 |
| ????11 | ????U82993 | ????LELDEWAS | ?669-676 |
| ????12 | ????X96522 | ????LELDEWAS | ?674-681 |
| ????13 | ????X96526 | ????LELDEWAS | ?677-684 |
The purpose of this invention is to provide can with the single-minded bonded monoclonal antibody of AIDS virus O, this antibody has epi-position DE, particularly the specificity of epi-position ELDEWA.
The mouse hybridoma cell that can secrete with the single-minded bonded monoclonal antibody of AIDS virus O is 14D9, be preserved in China Committee for Culture Collection of Microorganisms common micro-organisms center (being called for short CGMCC) on 06 27th, 2002, preserving number is CGMCC № 0753.
Mouse hybridoma cell is that the monoclonal antibody 14D9 that produces of 14D9 can the distinctive ELDEWA-epi-position of specific recognition HIV-1 virus 0 type strain transmembrane protein gp41, and the entrained ELDKWA-of other HIV-1 virus subtype of nonrecognition, ELNKWA-and ELEKWA-epi-position.
Monoclonal antibody of the present invention is differentiating, is diagnosing the strain of HIV-1 virus O type, preparation to be used for HIV-1 O type virus strain infection passive immunization medicine and will to be used widely.With monoclonal antibody of the present invention is that the medicine of active ingredient is expected to be applied in the treatment acquired immune deficiency syndrome (AIDS).
The present invention will be further described below in conjunction with specific embodiment.
Description of drawings
Fig. 1 is monoclonal antibody of the present invention and the reorganization that has different epi-positions, the reacted electrophorogram of solubility gp41 fusion rotein.
Embodiment
The preparation process of the hybridoma cell line 14D9 in embodiment 1, muroid source:
1, one of synthetic contains the epitope polypeptide of the distinctive ELDEWA-epi-position of HIV-10 type strain transmembrane protein gp41, this epitope polypeptide contains multiple ELDEWA-immunology epi-position 4 times, and its amino acid residue sequence is: CELDEWAGELDEWAGELDEWAGELDEWA;
2, utilize MBS (m-maleimidobenzoyl-N-hydroxy succinimide ester) with above-mentioned epitope polypeptide and carrier proteins BSA coupling connection;
3, above-mentioned coupling matter is mixed with freund adjuvant that (weight ratio of two kinds of materials is coupling matter: immune Balb/c mouse freund adjuvant=1: 1), per two all immunity once.Use complete freund adjuvant first, use incomplete freund adjuvant later on.Each immunizing antigen dosage is: contain the coupling matter of 10 microgram epitope polypeptides/time/only, immunity is 3 times altogether;
4, adopt conventional cell-fusion techniques to merge mouse boosting cell after the immunity and murine myeloma cell, and the preparation hybridoma, from hybridoma, filter out the hybridoma that can secrete ELDEWA-epitope specificity monoclonal antibody;
5, the clone hybridization oncocyte that clone hybridization knurl, acquisition can be secreted ELDEWA-epitope specificity monoclonal antibody is 14D9.
Embodiment 2, antibody of the present invention are to the specific recognition of HIV-1 virus O type strain ELDEWA-epi-position
Hybridoma cell line 14D9 excretory monoclonal antibody and the reorganization that has different epi-positions, solubility gp41 fusion rotein are carried out temperature bathe reaction, the result as shown in Figure 1, result from figure as can be seen, hybridoma cell line 14D9 excretory monoclonal antibody has specific recognition to HIV-1 virus O type strain ELDEWA-epi-position, among the figure, A: molecular weight protein; B: monoclonal antibody identification of the present invention has the rsgp41 (GST-rsgp41ELDEWA) (42KD) of ELDEWA epi-position; C: monoclonal antibody nonrecognition of the present invention has the rsgp41 (GST-rsgp41ELDKWA) of ELDKWA epi-position; D: monoclonal antibody nonrecognition GST of the present invention; E: monoclonal antibody identification of the present invention contains the GST-ELDEWA (26KD) of ELDEWA epi-position.
Claims (8)
1, the hybridoma cell line 14D9 in muroid source, CGMCC № 0753.
2, by preserving number be the monoclonal antibody of the hybridoma cell line 14D9 generation of CGMCC № 0753.
3, monoclonal antibody according to claim 2 is characterized in that: described antibody has AIDS virus O DE epitope specificity.
4, monoclonal antibody according to claim 3 is characterized in that: described antibody has AIDS virus O LDEW epitope specificity.
5, monoclonal antibody according to claim 3 is characterized in that: described antibody has AIDS virus O ELDEWA epitope specificity.
6, the application of any described monoclonal antibody in differentiating, diagnose the strain of HIV-1 virus O type among the claim 2-5.
7, any described monoclonal antibody is used for the application of HIV-1 O type virus strain infection passive immunization medicine among the claim 2-5 in preparation.
8, with any medicine that described monoclonal antibody is an active ingredient among the claim 2-5.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021253714A CN1238499C (en) | 2002-07-29 | 2002-07-29 | Antibody against AIDS virus O and its production cell series and use |
| AU2002325466A AU2002325466A1 (en) | 2002-07-29 | 2002-08-09 | The antibody directed against the hiv strain type o, the hybridoma cell line producing it and the uses thereof |
| PCT/CN2002/000551 WO2004011633A1 (en) | 2002-07-29 | 2002-08-09 | The antibody directed against the hiv strain type o, the hybridoma cell line producing it and the uses thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021253714A CN1238499C (en) | 2002-07-29 | 2002-07-29 | Antibody against AIDS virus O and its production cell series and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1472313A true CN1472313A (en) | 2004-02-04 |
| CN1238499C CN1238499C (en) | 2006-01-25 |
Family
ID=30121233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021253714A Expired - Fee Related CN1238499C (en) | 2002-07-29 | 2002-07-29 | Antibody against AIDS virus O and its production cell series and use |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN1238499C (en) |
| AU (1) | AU2002325466A1 (en) |
| WO (1) | WO2004011633A1 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5459060A (en) * | 1989-08-24 | 1995-10-17 | Bioclonetics Incorporated | Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1) |
| DE19809785C2 (en) * | 1998-03-08 | 2000-02-10 | Wolfgang Bergter | Radioimmune drug for the treatment of HIV-1 infection |
-
2002
- 2002-07-29 CN CNB021253714A patent/CN1238499C/en not_active Expired - Fee Related
- 2002-08-09 AU AU2002325466A patent/AU2002325466A1/en not_active Abandoned
- 2002-08-09 WO PCT/CN2002/000551 patent/WO2004011633A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002325466A8 (en) | 2004-02-16 |
| AU2002325466A1 (en) | 2004-02-16 |
| WO2004011633A1 (en) | 2004-02-05 |
| CN1238499C (en) | 2006-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zwick et al. | Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41 | |
| Beddows et al. | Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1 | |
| AT398080B (en) | IMMORTALIZED CELL LINE, METHOD FOR THEIR PRODUCTION AND METHOD FOR THE PRODUCTION OF MONOCLONAL ANTIBODIES, AND DIAGNOSTIC METHODS AND MEANS | |
| JPH02160800A (en) | Human immunodeficiency virus (hiv) | |
| EP1738764A1 (en) | Glycopeptides of the V3 loop of gp120 and derivatives; preparation and applications as HIV-1 vaccines. | |
| US6132721A (en) | Non-Toxic immunogens derived from a retroviral regulatory protein, antibodies, preparation method therefor, and pharmaceutical compositions containing same | |
| EP0492560A2 (en) | Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of HIV-1, and related peptides | |
| US6241986B1 (en) | Human monoclonal antibodies to the CD4-binding domain of HIV, uses thereof and synergistic neutralization of HIV | |
| KR930702509A (en) | Human immunodeficiency virus (HIV) immunotherapy | |
| JP2012500829A (en) | Broadly neutralizing antibodies are induced by synthetic peptides corresponding to overlapping neutralization determinants in the CBD1 epitope | |
| JPH05503851A (en) | Neutralizing and/or ADCC Mediating Monoclonal HIV Antibodies | |
| CN1668633A (en) | IgG Fc/HIV-gp120/C3d fusion protein | |
| CN1165344C (en) | Compsns. and methods for catalyzing hydrolysis of HIV gp120 | |
| CN1238499C (en) | Antibody against AIDS virus O and its production cell series and use | |
| US6200575B1 (en) | Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising them | |
| CN1472314A (en) | Immunity expression of AIDS virus O and its use | |
| Lockey et al. | Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees | |
| CN1172717C (en) | Method for treating AIDS and its preparing method | |
| US6083504A (en) | Human monoclonal antibodies directed against the transmembrane glycoprotein (GP41) of human immunodeficiency virus-1 (HIV-1) | |
| CN1226046C (en) | Non-toxic immunogens derived from a retroviral regulatory protein, antibodies, preparation mthod therefor and pharmaceutical compositions containing same | |
| Benjouad et al. | Effect of sialic acid removal on the antibody response to the third variable domain of human immunodeficiency virus type‐1 envelope glycoprotein | |
| EP0950063A1 (en) | Multiple branch peptide constructions | |
| CN103755805A (en) | Human monoclonal antibody with HIV-1 Env specificity | |
| Veljković et al. | Sequence similarity between human immunodeficiency virus type 1 envelope protein (gp120) and human proteins: A new hypothesis on protective antibody production | |
| REEVES et al. | Mouse monoclonal antibodies to human immunodeficiency virus glycoprotein 120 generated by repeated immunization with glycoprotein 120 from a single isolate, or by sequential immunization with glycoprotein 120 from three isolates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |